Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales
An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which is sold by Amgen.
Previous Post
STAT+: FDA pulls biologics license for chikungunya vaccine
Next Post
Advances in AI — August 2025
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago